110 related articles for article (PubMed ID: 9131143)
1. Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.
Kaufmann-Kolle P; Berger MR; Unger C; Eibl H
Adv Exp Med Biol; 1996; 416():165-8. PubMed ID: 9131143
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine.
Kaufmann-Kolle P; Drevs J; Berger MR; Kötting J; Marschner N; Unger C; Eibl H
Cancer Chemother Pharmacol; 1994; 34(5):393-8. PubMed ID: 8070005
[TBL] [Abstract][Full Text] [Related]
3. Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.
Kötting J; Berger MR; Unger C; Eibl H
Cancer Chemother Pharmacol; 1992; 30(2):105-12. PubMed ID: 1600590
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas.
Berger MR; Yanapirut P; Reinhardt M; Klenner T; Scherf HR; Schmeiser HH; Eibl H
Prog Exp Tumor Res; 1992; 34():98-115. PubMed ID: 1438807
[No Abstract] [Full Text] [Related]
5. Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration.
Erdlenbruch B; Jendrossek V; Gerriets A; Vetterlein F; Eibl H; Lakomek M
Cancer Chemother Pharmacol; 1999; 44(6):484-90. PubMed ID: 10550569
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic activity in vitro of free and liposomal alkylphosphocholines.
Zeisig R; Jungmann S; Arndt D; Schütt A; Nissen E
Anticancer Drugs; 1993 Feb; 4(1):57-64. PubMed ID: 8457716
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the tissue distribution of hexadecylphosphocholine and erucylphosphocholine.
Reitz RC; Kötting J; Unger C; Eibl H
Prog Exp Tumor Res; 1992; 34():143-52. PubMed ID: 1438797
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
Arndt D; Zeisig R; Fichtner I; Teppke AD; Fahr A
Breast Cancer Res Treat; 1999 Nov; 58(1):71-80. PubMed ID: 10634520
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations.
Zeisig R; Fichtner I; Arndt D; Jungmann S
Anticancer Drugs; 1991 Aug; 2(4):411-7. PubMed ID: 1797199
[TBL] [Abstract][Full Text] [Related]
10. In vitro investigations on the antineoplastic effect of hexadecylphosphocholine.
Yanapirut P; Berger MR; Reinhardt M; Schmähl D
Arzneimittelforschung; 1991 Jun; 41(6):652-5. PubMed ID: 1930356
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumoral activity of alkylphosphonates.
Ries UJ; Fleer EA; Breiser A; Unger C; Stekar J; Fenneberg K; Eibl H
Eur J Cancer; 1992; 29A(1):96-101. PubMed ID: 1445752
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133.
Stekar J; Hilgard P; Voegeli R; Maurer HR; Engel J; Kutscher B; Nössner G; Schumacher W
Cancer Chemother Pharmacol; 1993; 32(6):437-44. PubMed ID: 8258191
[TBL] [Abstract][Full Text] [Related]
14. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution.
Kötting J; Marschner NW; Neumüller W; Unger C; Eibl H
Prog Exp Tumor Res; 1992; 34():131-42. PubMed ID: 1438796
[No Abstract] [Full Text] [Related]
15. Hexadecylphosphocholine differs from conventional cytostatic agents.
Berger MR; Betsch B; Gebelein M; Amtmann E; Heyl P; Scherf HR
J Cancer Res Clin Oncol; 1993; 119(9):541-8. PubMed ID: 8392075
[TBL] [Abstract][Full Text] [Related]
16. Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro.
Jendrossek V; Erdlenbruch B; Hunold A; Kugler W; Eibl H; Lakomek M
Int J Oncol; 1999 Jan; 14(1):15-22. PubMed ID: 9863004
[TBL] [Abstract][Full Text] [Related]
17. D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
Hilgard P; Klenner T; Stekar J; Nössner G; Kutscher B; Engel J
Eur J Cancer; 1997 Mar; 33(3):442-6. PubMed ID: 9155530
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo.
Erdlenbruch B; Jendrossek V; Marx M; Hunold A; Eibl H; Lakomek M
Anticancer Res; 1998; 18(4A):2551-7. PubMed ID: 9703909
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of release and pharmacokinetics of hexadecylphosphocholine (miltefosine) in phosphatidyldiglycerol-based thermosensitive liposomes.
Rysin A; Paal M; Lokerse WJM; Wedmann B; Hossann M; Vogeser M; Winter G; Lindner LH
Biochim Biophys Acta Biomembr; 2021 Nov; 1863(11):183698. PubMed ID: 34283999
[TBL] [Abstract][Full Text] [Related]
20. Hexadecylphosphocholine: a new and selective antitumor drug.
Eibl H; Unger C
Cancer Treat Rev; 1990 Sep; 17(2-3):233-42. PubMed ID: 2272038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
